CARGO Therapeutics Inc. C... (CRGX)
3.69
-0.18 (-4.65%)
At close: Feb 20, 2025, 3:59 PM
3.66
-0.93%
After-hours: Feb 20, 2025, 05:56 PM EST
undefined% (undefined)
| Bid | 3.66 |
| Market Cap | 170.07M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -17.59 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.77 |
| Volume | 456,863 |
| Avg. Volume (20D) | 905,040 |
| Open | 3.90 |
| Previous Close | 3.87 |
| Day's Range | 3.68 - 3.95 |
| 52-Week Range | 3.00 - 33.92 |
| Beta | undefined |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cell...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2023
Employees 170
Stock Exchange NASDAQ
Ticker Symbol CRGX
Website https://cargo-tx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4, which is an increase of 8.25% from the latest price.
Buy 0.00%
Hold 85.71%
Sell 14.29%
3 weeks ago
-74.3%
Cargo Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
3 weeks ago
-3.37%
CARGO Therapeutics shares are trading lower after the company announced it discontinued its FIRCE-1 Phase 2 study.
